Our experience with this case suggested that PARP inhibitor may be a potential therapeutic option for FANCA mutation; PARP inhibitor combined with cisplatin may lead to synergistic efficacy with tolerable toxicity; and DDR gene mutation may respond to PARP inhibitor in HCC. This evidence concerns the gene FANCA and hepatocellular carcinoma.